Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first in class drugs that selectively trigger the body’s innate defenses without causing inflammation.

IDR products have major market potential for infectious disease, cancer, and inflammatory disease.  These products will significantly reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders.  IDR products will also benefit healthcare payors by reducing costs associated with hospitalization.

Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms.  The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression.  

Additional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

The scientific background on IDR-1, a prototype IDR compound, was recently published in the journal Nature Biotechnology (Nat. Biotech. Vol. 25 No. 4)